Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a growing health concern, with an estimated global incidence of over 1 million by 2025. In its intermediate and advanced stages, HCC remains a challenging condition to treat, despite a recently expanded array of systemic therapies, which continues to grow. Extensive...

Full description

Saved in:
Bibliographic Details
Published inLiver cancer international Vol. 4; no. 1; pp. 13 - 27
Main Authors Gray, Simon, Lamarca, Angela, McNamara, Mairéad G., Edeline, Julien, Piper‐Hanley, Karen, Valle, Juan W., Hubner, Richard A.
Format Journal Article
LanguageEnglish
Published Hoboken John Wiley & Sons, Inc 01.03.2023
Subjects
Ablation
biomarker
Cancer therapies
Clinical medicine
Confidence intervals
Cytokeratin
Deoxyribonucleic acid
DNA
FDA approval
Hepatitis B
Hepatitis C
hepatocellular
Liver cancer
Liver diseases
locoregional
Magnetic resonance imaging
Medical prognosis
Oncology
predictive
prognostic
Radiomics
systemic
Tomography
Tumors
Vascular endothelial growth factor
Asia
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is a growing health concern, with an estimated global incidence of over 1 million by 2025. In its intermediate and advanced stages, HCC remains a challenging condition to treat, despite a recently expanded array of systemic therapies, which continues to grow. Extensive efforts have accordingly been made to identify predictive factors to guide treatment decisions. However, currently, only one predictive biomarker is in widespread clinical use, namely elevated alpha‐fetoprotein for second‐line systemic therapy with ramucirumab. This article reviews known prognostic and predictive biomarkers for patients with HCC who are treated with locoregional and systemic therapies, including recent controversies around the potential impact of HCC aetiology on the efficacy of systemic therapies. While factors predicting treatment response in intermediate‐ or advanced‐stage hepatocellular carcinoma have been widely sought, only one is in routine clinical use. This is a review of current factors related to patient demographics, disease characteristics (including radiomics) and tissue‐ and plasma‐based biomarkers (including liquid biopsy techniques) which may influence prognosis or response to specific therapies in patients with hepatocellular carcinoma.
ISSN:2642-3561
2642-3561
DOI:10.1002/lci2.62